Kiniksa Pharmaceuticals International (KNSA) Net Cash Flow (2017 - 2026)

Kiniksa Pharmaceuticals International's Net Cash Flow history runs 10 years deep, the most recent figure standing at $24.4 million for Q1 2026.

• Quarterly Net Cash Flow rose 192.09% year-over-year to $24.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.8 million (up 104.44% YoY) and the FY2025 annual result came in at -$18.0 million, down 123.78% from the prior year.
• Net Cash Flow was $24.4 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from -$9.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $86.2 million in Q4 2024 and bottomed at -$59.1 million in Q1 2022.
• A 5-year average of $4.0 million and a median of -$1.9 million in 2024 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 1116.6% — and 2024, when it jumped 973.05%.
• Kiniksa Pharmaceuticals International's Net Cash Flow stood at -$53.0 million in 2022, then surged by 81.39% to -$9.9 million in 2023, then soared by 973.05% to $86.2 million in 2024, then plunged by 110.74% to -$9.3 million in 2025, then jumped by 362.97% to $24.4 million in 2026.
• Business Quant data shows KNSA's Net Cash Flow at $24.4 million in Q1 2026, -$9.3 million in Q4 2025, and -$17.2 million in Q3 2025.